Algert Global’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Algert Global’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,150	Closed	-$729K	–	1293
2023 Q2	$729K	Buy	+7,150	New	+$677K	0.03%	728
2022 Q4	–	Sell	-15,372	Closed	-$386K	–	1331
2022 Q3	$386K	Sell	15,372 -13,140	-46%	-$364K	0.02%	881
2022 Q2	$866K	Buy	+28,512	New	+$851K	0.07%	537

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Algert Global's RETA Position: Q3 2023 in Review

Algert Global sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,150 shares — an estimated $729K sold.

Algert Global first reported a position in RETA in Q2 2022 and held it in 3 quarters. The position peaked at $866K in Q2 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Algert Global reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Algert Global sold 7,150 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $729K.
Algert Global first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2022 and held it in 3 quarters.
Algert Global's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $866K in Q2 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Algert Global's 13F filing for Q3 2023, filed 13 Nov 2023.